November 03, 2022 16:05 ET ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, November 10, […]
-Webinar to feature presentation from immunotherapy experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D., on Monday, November 7th at 11 a.m. ET- October 31, 2022 08:00 ET ROCKVILLE, Md., Oct. 31, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat
– Data to be featured in an oral presentation highlighting the encouraging biological activity of VCN-01 treatment in combination with durvalumab- October 24, 2022 08:00 ET ROCKVILLE, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration October 12, 2022 08:00 ET ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and
Synthetic Biologics Rebrands as Theriva Biologics Read More »
September 30, 2022 08:00 ET Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastoma ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from
September 27, 2022 08:00 ET – The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 – ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a
DELIVERING A NEW CLASS OF ONCOLYTIC VIRUS THERAPEUTICS ABOUT THERIVA™ Theriva is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies are designed to enable systemic delivery and have the potential to enhance current standard-of-care therapies, offering patients with difficult-to-treat
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11,
